… comparison of CAR-T therapy and BiTE in oncohematological diseases. Dr. Subklewe gave a short excursion into the basics … production and release of the tight junction at the blood-brain barrier resulting in the influx of CAR T-cells … cells, and structural organ cells and on reformatting the blood-brain barrier. He mentions the ZUMA-1 trial and …

… Di Majo (Italy) for the abstract SINGLE UNRELATED CORD-BLOOD VERSUS UNMANIPULATED HAPLOIDENTIAL HEMATOPOIETIC STEM … CELL THERAPY WITH MEMORY T LYMPHOCYTES TO TREAT INFECTIOUS DISEASES IN IMMUNCOMPROMISED PATIENTS Yuhua Ru (China) for …

… applications beyond oncology (notably in autoimmune diseases), risk stratification, dual-targeting approaches and … CAR+ and CAR- cells from the infusion product and patient blood post-infusion were compared. Fitness of CAR+ cells at … rates and longer PFS. A multi-omics single-cell atlas from blood samples from 57 patients showed a strong association …

… practical review of the current standard of care for these diseases, including IgM monoclonal gammopathies of clinical … (in bone marrow, and in some studies in peripheral blood) Standard first line therapy in transplant eligible …

… EBMT risk score (AUC 0.70 vs. 0.65). Arai et al. (Blood Advances, 2019) also used an alternating decision tree … reasons, among them are new cancers and cardiovascular diseases. 44% of patients are not adherent to health care …

… particularly, long-term toxicity and the risk of secondary diseases remain major concerns. Marion Rougé then presented a … in 1966 for people with neutropenia or undergoing blood cancer treatment.  There is a lack of evidence and …